Axsome Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Drug approval progress means the company could earn revenue from a new medicine soon.
Shows what company promises to pay leaders if they're fired, important for understanding management stability.
Shareholders voted to keep these leaders overseeing the company for three more years.
Ending lawsuits over a drug removes legal risks and costs that could hurt profits.
Shows how much money the company made or lost, helping you understand if the business is growing.
Drug approval means the company can now sell this medicine to patients, creating new revenue.
Updated presentation helps investors and stakeholders understand the company's current strategy.
Stocky reads Axsome Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Axsome Therapeutics, Inc.'s most recent tracked filing was a 8-K on 15 Jul 2026: FDA accepts AXS-12 new drug application for cataplexy.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.